Alexander A Iyer1,2, Julie R Barzilay3, Holly K Tabor4. 1. Stanford Center for Biomedical Ethics, Department of Medicine, Stanford University, Stanford, CA, USA. 2. Department of Bioethics, National Institutes of Health Clinical Center, Bethesda, MD, USA. 3. Stanford University School of Medicine, Stanford, CA, USA. 4. Stanford Center for Biomedical Ethics, Department of Medicine, Stanford University, Stanford, CA, USA. hktabor@stanford.edu.
Abstract
PURPOSE: Advances in gene therapy and precision medicine have led to a growing number of novel treatments for rare genetic diseases. Patients/families may lack access to up-to-date, accurate, and relevant information about these treatments. Social media offers one potentially important resource for these communities. Our goal was to understand how patients/families with spinal muscular atrophy (SMA)-a rare genetic condition-used social media to share, consume, and evaluate information about the novel treatment nusinersen (Spinraza) following the drug's approval. METHODS: We conducted qualitative, semistructured interviews with 20 SMA patients or parents of patients, deriving themes and subthemes through content and thematic network analysis. Participants also completed a demographic survey. RESULTS: Participants described leveraging social media to learn about nusinersen treatment, make informed treatment decisions, and advocate for/access treatment. They also described critically evaluating the trustworthiness of nusinersen-related information on social media and the privacy risks of social media use. CONCLUSION: Patients/families used social media to navigate the new and dynamic landscape of nusinersen treatment for SMA, while attempting to mitigate misinformation and privacy risks. As new treatments become available, providers and patients/families may benefit from proactively discussing social media use, so as to maximize important benefits while minimizing risks.
PURPOSE: Advances in gene therapy and precision medicine have led to a growing number of novel treatments for rare genetic diseases. Patients/families may lack access to up-to-date, accurate, and relevant information about these treatments. Social media offers one potentially important resource for these communities. Our goal was to understand how patients/families with spinal muscular atrophy (SMA)-a rare genetic condition-used social media to share, consume, and evaluate information about the novel treatment nusinersen (Spinraza) following the drug's approval. METHODS: We conducted qualitative, semistructured interviews with 20 SMA patients or parents of patients, deriving themes and subthemes through content and thematic network analysis. Participants also completed a demographic survey. RESULTS: Participants described leveraging social media to learn about nusinersen treatment, make informed treatment decisions, and advocate for/access treatment. They also described critically evaluating the trustworthiness of nusinersen-related information on social media and the privacy risks of social media use. CONCLUSION: Patients/families used social media to navigate the new and dynamic landscape of nusinersen treatment for SMA, while attempting to mitigate misinformation and privacy risks. As new treatments become available, providers and patients/families may benefit from proactively discussing social media use, so as to maximize important benefits while minimizing risks.
Authors: Alyssa M Burgart; David Magnus; Holly K Tabor; Erin Daksha-Talati Paquette; Joel Frader; Jaqueline J Glover; Brian M Jackson; Charlotte H Harrison; David K Urion; Robert J Graham; John F Brandsema; Chris Feudtner Journal: JAMA Pediatr Date: 2018-02-01 Impact factor: 16.193
Authors: Basil T Darras; Claudia A Chiriboga; Susan T Iannaccone; Kathryn J Swoboda; Jacqueline Montes; Laurence Mignon; Shuting Xia; C Frank Bennett; Kathie M Bishop; Jeremy M Shefner; Allison M Green; Peng Sun; Ishir Bhan; Sarah Gheuens; Eugene Schneider; Wildon Farwell; Darryl C De Vivo Journal: Neurology Date: 2019-04-24 Impact factor: 9.910
Authors: S Anne Moorhead; Diane E Hazlett; Laura Harrison; Jennifer K Carroll; Anthea Irwin; Ciska Hoving Journal: J Med Internet Res Date: 2013-04-23 Impact factor: 5.428
Authors: Emily G Miller; Amanda L Woodward; Grace Flinchum; Jennifer L Young; Holly K Tabor; Meghan C Halley Journal: Genet Med Date: 2021-07-19 Impact factor: 8.864